I last discussed Syneos Health on August 15, in a popular post on early stage commercialization. When I checked for recent news I discovered that Syneos Health received a commercialization setback in India for the QL2107 Injection. [T]he Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has rejected its Phase … Continue reading Stuck at Second: Syneos Health Setback in India